Author:
Choi Yiseul,Kim Jaeyeon,Rhee Yumie,Park Jin Hoo,Nam Woong,Park Wonse
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Gullberg B, Johnell O, Kanis J (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413
2. Green JR (2003) Antitumor effects of bisphosphonates. Cancer: Interdiscip Int J Am Cancer Soc 97:840–847
3. Pozzi S, Raje N (2011) The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 16:651–662. https://doi.org/10.1634/theoncologist.2010-0225
4. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897
5. Janovská Z (2012) Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy. Acta Medica (Hradec Kralove) 55:111–115